Tesaro (TSRO) PT Raised to $139 at Wedbush

October 10, 2016 6:54 AM EDT
Get Alerts TSRO Hot Sheet
Price: $150.53 +0.85%

Rating Summary:
    14 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 22 | Down: 32 | New: 34
Trade TSRO Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Wedbush analyst David Nierengarten reiterated an Outperform rating and boosted his price target on Tesaro (NASDAQ: TSRO) to $139.00 (from $107.00) as the NOVA trial data supports possible approval in all platinum-sensitive patients.

Nierengarten commented, "We see the clinical benefit of niraparib in HRD-negative patients as likely leading to approval in the entire platinum-sensitive ovarian market. Furthermore, we see the lack of requirement for a companion diagnostic for niraparib in these patients as a potential advantage over competing PARP inhibitors."

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $99.26 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Add Your Comment